3-n-methylspiperone has been researched along with Cerebral Pseudosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Engelbrecht, V; Hefter, H; Nebeling, B; Schlaug, G; Seitz, RJ; Stöcklin, G; Weiss, P | 1 |
| Arnold, S; Engelbrecht, V; Hefter, H; Kuwert, T; Schlaug, G; Seitz, RJ; Stöcklin, G | 1 |
1 trial(s) available for 3-n-methylspiperone and Cerebral Pseudosclerosis
| Article | Year |
|---|---|
Neurological impairment and recovery in Wilson's disease: evidence from PET and MRI.
Topics: Adult; Brain Chemistry; Chelating Agents; Deoxyglucose; Female; Fluorodeoxyglucose F18; Glucose; Hepatolenticular Degeneration; Humans; Magnetic Resonance Imaging; Male; Neostriatum; Nervous System; Receptors, Dopamine D2; Spiperone; Tomography, Emission-Computed | 1996 |
1 other study(ies) available for 3-n-methylspiperone and Cerebral Pseudosclerosis
| Article | Year |
|---|---|
Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine-therapy in Wilson's disease.
Topics: Adult; Basal Ganglia; Brain; Deoxyglucose; Dopamine Agents; Fluorine Radioisotopes; Glucose; Hepatolenticular Degeneration; Humans; Magnetic Resonance Imaging; Male; Neurons; Penicillamine; Receptors, Dopamine D2; Spiperone; Tomography, Emission-Computed | 1994 |